NasdaqGM:ATAIPharmaceuticals
AtaiBeckley (ATAI) Stock Looks Expensive With Takeover Optimism Priced In
AtaiBeckley stock has delivered a very large 3 year gain, and the broader valuation checks currently lean expensive, with the market multiple suggesting investors are paying up for the story after the Eli Lilly buyout announcement and recent regulatory tailwinds.
AtaiBeckley has returned about 248.5% over the past 3 years, which puts a lot of recent optimism into the current share price.
The agreed Eli Lilly acquisition and supportive FDA guidance on psychedelic therapies can underpin...